ROIV
Roivant Sciences Ltd.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #917
- Final score
- 22.02
- Years on list
- 3
↘ Down 566 since 2023
Compare · Up to four Russell 1000 companies
Put them side by side
Select two, three, or four Russell 1000 companies to compare their overall rank, year-by-year trajectory, and scores down to the category level.
- ROIV· Roivant Sciences Ltd.
- APLS· Apellis Pharmaceuticals, Inc.
- MEDP· Medpace Holdings, Inc.
Figure 01 · Side-by-side summary
The headline numbers
APLS
Apellis Pharmaceuticals, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #913
- Final score
- 22.43
- Years on list
- 3
↘ Down 83 since 2023
MEDP
Medpace Holdings, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #935
- Final score
- 19.94
- Years on list
- 3
↘ Down 78 since 2023
Figure 02 · Rank trajectory
Where each line is going
Lower is better. The y-axis is inverted so a rising line means an improving rank. Missing years mean the company didn't make the top 100 that year.
Figure 03 · Pillar profile · 2025
Where each one wins
Latest-year ESG pillar scores, 0–100. The shaded bar shows relative strength across the selected companies for each pillar.
| Pillar | ROIV | APLS | MEDP |
|---|---|---|---|
| Climate Change | 25.3 | 16.3 | 20.3 |
| Employee Relations | 31.5 | 30.6 | 25.4 |
| Environment | 15.0 | 15.2 | 9.8 |
| Stakeholders & Society | 20.6 | 18.2 | 12.8 |
| Human Rights | 4.1 | 23.8 | 23.2 |
| Governance | 26.2 | 26.4 | 24.7 |
| Performance Rating | 32.8 | 48.3 | 41.5 |